Proneurotensin predicts cardiovascular disease in an elderly population.
J Clin Endocrinol Metab. 2018 Mar 13;:
Authors: Fawad A, Bergmann A, Struck J, Nilsson PM, Orho-Melander M, Melander O
Abstract
Context: The gut hormone neurotensin promotes fat absorption, diet-induced weight gain and liver steatosis. Its stable precursor-hormone fragment "proneurotensin" predicts cardiometabolic disease in middle-aged populations, especially in women.
Objective: To test if proneurotensin predicts cardiovascular disease (CVD) and diabetes development in an elderly population and whether there are gender differences in this respect.
Design, Setting and Participants: Fasting proneurotensin was measured in plasma from 4804 participants (mean age 69±6 years) of the Malmö Preventive Project (MPP) and subjects were followed up for development of CVD and diabetes during 5.4 years.
Main Outcome Measures: Multivariate adjusted Cox proportional hazard models CVD were used to relate the proneurotensin to the risk of incident CVD and diabetes in all subjects and in gender-stratified analyses.
Results: In total, there were 456 first CVD events and 222 incident cases of diabetes. The hazard ratio [HR (95% confidence interval)] for CVD per 1 standard deviation (SD) increment of proneurotensin was 1.10 (1.01-1.21); P=0.037, and the above vs below median HR was 1.27 (1.06-1.54); P=0.011, with similar effect sizes in both gender. There was no significant association between proneurotensin and incident diabetes in the entire population (P=0.52) or among men (P=0.52). However, in women proneurotensin predicted diabetes incidence with a per 1SD increment HR of 1.28 (1.30-1.59); P=0.025 and an above vs below median HR of 1.41 (1.10- 1.80); P=0.007.
Conclusions: In the elderly population, proneurotensin independently predicts development of CVD in both gender whereas it only predicts diabetes in women.
PMID: 29546332 [PubMed - as supplied by publisher]
http://ift.tt/2FT6sT2
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου